Foreign firms deny trials caused deaths in India amid concerns over reporting norms
This article was originally published in Scrip
Multinationals undertaking clinical trials in India such as Novartis, Merck & Co and the biopharmaceutical services company, Quintiles, have refuted claims that their studies have caused several deaths. The companies caution that any knee-jerk reaction to tighten policy irrationally may also hurt large non-industry-sponsored trials for developing world diseases in the country.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.